Smith & Nephew SN.L · GBp
Health Care · Health Care Equipment & Supplies · LSE · 🇬🇧 United Kingdom
FTSE 100
1,140.50p
-1.77%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Smith & Nephew
Its shares trade on LSE under the ticker SN.L. It has been listed since 13 August 1951. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of $6.29bn and net income of $638.1m. At that date it held total assets of $10.46bn and shareholders' equity of $5.29bn.
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire. The firm is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 13 Aug 1951
- Employees
- 17,914
- Website
- smith-nephew.com ↗
Leadership
Pay as last reported
- Mr. Rupert SoamesNon-Executive Independent Chairman of the Board$579,000
- Mr. Deepak NathChief Executive Officer, Executive Director, since 2022$7.8m
- Mr. John RogersChief Financial Officer, Executive Director, since 2023$2.0m
- Mr. Paul ConnollyPresident - Global Operations
- Mr. Craig GaffinPresident - Orthopaedics
- Dr. Rohit KashyapPresident - Advanced Wound Management and Global Commercial Operations
- Mr. Vasant PadmanabhanPresident Research & Development, ENT and Emerging Markets
- Mr. Scott SchaffnerPresident - Sports Medicine
- Ms. Elga LohlerChief Human Resources Officer
- Ms. Alison ParkesChief Compliance Officer
- Ms. Helen BarracloughGroup General Counsel, Company Secretary
- Mr. Phil CowdyChief Corporate Development and Corporate Affairs Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 70
- Social
- 99
- Governance
- 92
- Direct emissions (scope 1)
- 15,901 t
- Energy emissions (scope 2)
- 59,012 t
- Value chain emissions (scope 3)
- 1,276,079 t
- Women in the workforce
- 43%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Smith & Nephew PLC has a strong brand reputation in the healthcare industry.
- Being a global company, Smith & Nephew has a widespread distribution network.
- The company has a diverse product portfolio offering various innovative medical devices.
- Smith & Nephew has a strong research and development capability, allowing it to constantly introduce new products and stay ahead of competitors.
- The company has a highly skilled and experienced workforce.
Weaknesses
- Smith & Nephew may face challenges in effectively managing its global operations due to geographical and cultural differences.
- The company's reliance on external suppliers for raw materials may lead to supply chain vulnerabilities.
- Smith & Nephew's pricing strategy may not always be competitive compared to other players in the industry.
- The company may encounter regulatory barriers and compliance challenges in different markets.
- Smith & Nephew's dependency on a few key markets for a significant portion of its revenue exposes it to market risks.
Opportunities
- The increasing global healthcare expenditure provides an opportunity for Smith & Nephew to expand its market presence and generate higher revenue.
- Advancements in medical technology present opportunities for the company to develop and launch new innovative products.
- Entering emerging markets with rising healthcare demands can open up new growth prospects for Smith & Nephew.
- The aging population in many countries creates a growing market for joint replacement surgeries and other medical interventions offered by the company.
- Healthcare policies and regulations promoting the use of medical devices can drive the demand for Smith & Nephew's products.
Threats
- The intense competition in the healthcare industry poses threats to Smith & Nephew's market share and profitability.
- Fluctuating raw material prices can impact the company's manufacturing costs and profit margins.
- Economic downturns and financial uncertainties in key markets may affect the demand for expensive medical devices.
- Stringent regulations and compliance requirements can disrupt the company's operations and increase costs.
- Technological advancements by competitors may undermine Smith & Nephew's competitive advantage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.